Stock Market Symbols GIB.A (TSX) GIB (NYSE) cgi.com/newsroom MONTRÉAL, July 24, 2024 /PRNewswire/ – CGI (TSX: GIB.A) (NYSE: GIB) will release results for its third quarter fiscal year 2024, ended June 30, 2024, on Wednesday, July 31, 2024 before the markets open. Management will host a…
Month: July 2024
Stock Market Symbols GIB.A (TSX) GIB (NYSE) cgi.com/newsroom MONTRÉAL, July 24, 2024 /PRNewswire/ – CGI (TSX: GIB.A) (NYSE: GIB) will release results for its third quarter fiscal year 2024, ended June 30, 2024, on Wednesday, July 31, 2024 before the markets open. Management will host a…
MARLBOROUGH, Mass., July 24, 2024 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.120 billion during the second quarter of 2024, growing 14.5 percent on a reported basis, 16.1 percent on an operational1 basis and 14.7 percent on an organic2 basis, all…
MARLBOROUGH, Mass., July 24, 2024 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.120 billion during the second quarter of 2024, growing 14.5 percent on a reported basis, 16.1 percent on an operational1 basis and 14.7 percent on an organic2 basis, all…
Treatment of pre-clinical subjects showed cognitive benefits that suggest HT-ALZ’s mode of action may involve a reduction in brain inflammation, thereby improving cognitive outcomes for Alzheimer’s patients. HT-ALZ’s pre-clinical significance lies in its ability to demonstrate marked…
Treatment of pre-clinical subjects showed cognitive benefits that suggest HT-ALZ’s mode of action may involve a reduction in brain inflammation, thereby improving cognitive outcomes for Alzheimer’s patients. HT-ALZ’s pre-clinical significance lies in its ability to demonstrate marked…
– Senior Executive and Thought Leader in Brain Health with Nearly Three Decades of Global Pharmaceutical Experience – – Served as Neuroimmunology Franchise Head Responsible for Roche’s Blockbuster Launch of Multiple Sclerosis Therapy Ocrevus® – NEW YORK, July 24, 2024 /PRNewswire/ –…
– Senior Executive and Thought Leader in Brain Health with Nearly Three Decades of Global Pharmaceutical Experience – – Served as Neuroimmunology Franchise Head Responsible for Roche’s Blockbuster Launch of Multiple Sclerosis Therapy Ocrevus® – NEW YORK, July 24, 2024 /PRNewswire/ –…
GLEN ALLEN, Va., July 24, 2024 /PRNewswire/ — Hamilton Beach Brands Holding Company (NYSE: HBB) announced today that it will release its 2024 second quarter financial results and file its 10-Q for the quarter ended June 30, 2024, after the close of the market on Wednesday, July 31, 2024….
GLEN ALLEN, Va., July 24, 2024 /PRNewswire/ — Hamilton Beach Brands Holding Company (NYSE: HBB) announced today that it will release its 2024 second quarter financial results and file its 10-Q for the quarter ended June 30, 2024, after the close of the market on Wednesday, July 31, 2024….